Tokyo, Japan I March 23, 2012 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that it has filed for approval in Japan to market AMG 162 (denosumab), a gene recombinant drug for osteoporosis.
Denosumab is the world’s first fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation, function and survival approved for therapeutic use. Daiichi Sankyo has been working on denosumab since 2007, when it licensed the rights from Amgen to develop and market this antibody in Japan.
Daiichi Sankyo is participating in the global phase III trial of adjuvant treatment for women with early-stage breast cancer, and is conducting phase II trials for Japanese patients with rheumatoid arthritis and giant cell tumor of bone, respectively.
Daiichi Sankyo received approval in Japan on January 18th 2012 to market RANMARKⓇ as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors.
With denosumab, Daiichi Sankyo aims to benefit patients and medical professionals by providing a new approach to therapy for osteoporosis.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimise growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about Amgen’s pioneering science and vital medicines, visit www.amgen.com. Follow them on www.twitter.com/amgen.
SOURCE: Daiichi Sankyo
Post Views: 52
Tokyo, Japan I March 23, 2012 I Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), today announced that it has filed for approval in Japan to market AMG 162 (denosumab), a gene recombinant drug for osteoporosis.
Denosumab is the world’s first fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation, function and survival approved for therapeutic use. Daiichi Sankyo has been working on denosumab since 2007, when it licensed the rights from Amgen to develop and market this antibody in Japan.
Daiichi Sankyo is participating in the global phase III trial of adjuvant treatment for women with early-stage breast cancer, and is conducting phase II trials for Japanese patients with rheumatoid arthritis and giant cell tumor of bone, respectively.
Daiichi Sankyo received approval in Japan on January 18th 2012 to market RANMARKⓇ as treatment for bone complications stemming from multiple myeloma and bone metastases from solid tumors.
With denosumab, Daiichi Sankyo aims to benefit patients and medical professionals by providing a new approach to therapy for osteoporosis.
About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimise growth opportunities across the value chain. For more information, please visit: www.daiichisankyo.com.
About Amgen
Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science’s promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. To learn more about Amgen’s pioneering science and vital medicines, visit www.amgen.com. Follow them on www.twitter.com/amgen.
SOURCE: Daiichi Sankyo
Post Views: 52
